Daiichi Sankyo Company, Limited
Announcement on the Transfer of Shares of Daiichi Sankyo Healthcare (Change in Consolidated Subsidiary)
All shares of Daiichi Sankyo Healthcare are transferred to Suntory Holdings for a total of 246.5 billion yen. The transfer will be implemented in phases starting June 2026 and completed by June 2029.
Key Figures
- Transfer Price: 246.5 billion yen (planned)
- Number of Shares Transferred: 10,000 shares (100% owned shares)
- Daiichi Sankyo Healthcare Net Sales (Fiscal Year Ending March 2025): 76,049 million yen
AI要約
Overview of the Transfer
Daiichi Sankyo Company, Limited has decided to transfer all shares of its consolidated subsidiary, Daiichi Sankyo Healthcare Co., Ltd., to Suntory Holdings Limited and concluded the share transfer agreement on April 15, 2026. The total transfer price is planned at 246.5 billion yen, with 30% of the shares transfer scheduled to begin in June 2026 and complete the transfer of all shares by June 2029. The purpose of the transfer is to promote the business growth of Daiichi Sankyo Healthcare by leveraging Suntory HD’s strengths, while Daiichi Sankyo will focus its resources on its innovative pharmaceutical business.
Overview and Future Outlook of the Transferred Company
Daiichi Sankyo Healthcare, the company subject to the transfer, mainly develops OTC pharmaceuticals along with functional skincare, oral care, and food products. Its net sales for the fiscal year ending March 2025 were 76,049 million yen, operating income was 12,922 million yen, and net income was 8,997 million yen, showing steady performance. The impact on consolidated results for the fiscal year ending March 2027 due to the transfer is currently under review, with revenue recognition related to the share transfer expected in the fiscal year ending March 2028.
